In this blog article, Dr. Dan Milner, Chief Medical Officer of the American Society for Clinical Pathology, discusses his experience about his participation in the 2022 Summit on Cancer Health Disparities held on April 29-May1, 2022.
On June 20, 2023, the U.S. Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) in combination with enzalutamide for patients with
By Dr. Chepsy Philip Believer’s Church Medical College Hospital Myeloproliferative – Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Combination chemoimmunotherapy with the chemo regimen R-CHOP (Rituximab, cyclophosphamide, doxorubicin,